[HTML][HTML] Tuberculosis: epidemiology and control
G Sulis, A Roggi, A Matteelli… - Mediterranean journal of …, 2014 - ncbi.nlm.nih.gov
Tuberculosis (TB) is a major public health concern worldwide: despite a regular, although
slow, decline in incidence over the last decade, as many as 8.6 million new cases and 1.3 …
slow, decline in incidence over the last decade, as many as 8.6 million new cases and 1.3 …
Extensively drug-resistant tuberculosis: epidemiology and management
A Matteelli, A Roggi, ACC Carvalho - Clinical epidemiology, 2014 - Taylor & Francis
The advent of antibiotics for the treatment of tuberculosis (TB) represented a major
breakthrough in the fight against the disease. However, since its first use, antibiotic therapy …
breakthrough in the fight against the disease. However, since its first use, antibiotic therapy …
[HTML][HTML] Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: nationwide programmatic achievements
A Piubello, MB Souleymane, S Hassane-Harouna… - Respiratory …, 2020 - Elsevier
Abstract Background In Niger, the Shorter Treatment Regimen (STR) has been implemented
nationwide for rifampicin resistant tuberculosis (RR-TB), since 2008. No previous publication …
nationwide for rifampicin resistant tuberculosis (RR-TB), since 2008. No previous publication …
High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss
MB Souleymane, A Piubello, IM Lawan… - European …, 2021 - Eur Respiratory Soc
The short treatment regimen (STR) achieves a> 80% cure in rifampicin-resistant tuberculosis
(RR-TB) patients. However, ototoxicity induced by the injectable is a concern. This is the first …
(RR-TB) patients. However, ototoxicity induced by the injectable is a concern. This is the first …
[HTML][HTML] Course of adverse events during short treatment regimen in patients with rifampicin-resistant tuberculosis in Burundi
F Ciza, T Gils, M Sawadogo, T Decroo, A Roggi… - Journal of Clinical …, 2020 - mdpi.com
The introduction of the nine-month short-treatment regimen (STR) has drastically improved
outcomes of rifampicin-resistant tuberculosis (RR-TB) treatment. Adverse events (AE) …
outcomes of rifampicin-resistant tuberculosis (RR-TB) treatment. Adverse events (AE) …
The impact of Xpert® MTB/RIF depends on service coordination: experience in Burkina Faso
I Moyenga, A Roggi, G Sulis, S Diande… - … of Tuberculosis and …, 2015 - ingentaconnect.com
Translating the potential of Xpert® MTB/RIF into more effective tuberculosis (TB) care and
control in low-income settings is challenged by operational issues. We report the experience …
control in low-income settings is challenged by operational issues. We report the experience …
Retrospective diagnosis of West Nile virus infection in a patient with meningoencephalitis in Tuscany, Italy
MG Cusi, A Roggi, C Terrosi… - Vector-Borne and …, 2011 - liebertpub.com
We report a case of West Nile virus (WNV) infection in a symptomatic woman living in
Tuscany in 2007. A retrospective analysis on cerebrospinal fluids drawn from people …
Tuscany in 2007. A retrospective analysis on cerebrospinal fluids drawn from people …
[HTML][HTML] Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per …
HG Ouedraogo, A Matteelli, G Sulis… - Annals of Clinical …, 2020 - Springer
Background To evaluate the pharmacokinetic of plasma lopinavir (LPV) and ritonavir (RTV)
when co-administered with three times weekly (TPW) rifabutin (RBT) at a dose of either 150 …
when co-administered with three times weekly (TPW) rifabutin (RBT) at a dose of either 150 …
[HTML][HTML] Mycobacterium sherrisii pulmonary disease, Burkina Faso
E Borroni, G Badoum, DM Cirillo… - Emerging Infectious …, 2015 - ncbi.nlm.nih.gov
(MAC), M. kansasii, M. abscessus, and M. xenopi (1). Little is known about the role of NTM in
pulmonary disease in countries with a high prevalence of tuberculosis (TB). In such settings …
pulmonary disease in countries with a high prevalence of tuberculosis (TB). In such settings …
[HTML][HTML] Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients
S Kouanda, HG Ouedraogo, K Cisse… - BMC Infectious …, 2020 - Springer
Background This study aimed to assess the pharmacokinetic profile of 150 mg rifabutin
(RBT) taken every other day (every 48 h) versus 300 mg RBT taken every other day (EOD) …
(RBT) taken every other day (every 48 h) versus 300 mg RBT taken every other day (EOD) …